- About Us
- Guidelines
-
The Author ensures that the research has been conducted responsibly and ethically with adherence to all relevant regulations. read more..
- For Authors
- For Reviewer
- Manuscript Guidelines
- Membership
- Publication Ethics
-
- Journals
- Reprints
- e-Books
- Videos
- Indexing
- Contact Us
COVID-19
- Submissions
Abstract
Open Journal of Cardiology & Heart Diseases
Vutrisiran: A Game-Changer in TTR Amyloidosis Therapy
-
Open or CloseVaibhav Sharma* and Vishakha Maheshwari
M.B.B.S.: Center for Advanced Heart Failure and Heart Transplant, University of Texas Health Science Center, Houston, Texas
*Corresponding author:Vaibhav Sharma, M.B.B.S., Center for Advanced Heart Failure and Heart Transplant, University of Texas Health Science Center, Houston, Texas
Submission: February 10, 2025;Published: April 22, 2025
ISSN: 2578-0204Volume4 Issue 5
Abstract
Transthyretin (TTR) amyloidosis represents a significant challenge to modern medicine, characterized by the progressive accumulation of misfolded proteins that affect multiple organ systems. Here, we present a review of the advent of vutrisiran as a breakthrough therapeutic choice that focuses on its mechanism of action, clinical efficacy, safety profile, and position in the present therapeutic paradigm. In recent clinical trials, vutrisiran has been causally linked to the potential modulation of disease progression via its innovative RNA interference mechanism, thereby providing renewed hope for patients with hereditary and wild-type TTR amyloidosis.
Editor In Chief
.jpg)
Signup for Newsletter
Quick Links
Editorial Board Registrations
Submit your Article
Best Paper of the Volume
Reprints
Refer a Friend
Advertise With UsOur Recent Edition
.jpg)
Top Editors
.jpg)
.bmp)
.jpg)
.png)
.jpg)
.jpg)
.png)
.png)
.png)
Financial Support
Sponsors
Latest e-Books
Latest Video
a Creative Commons Attribution 4.0 International License. Based on a work at www.crimsonpublishers.com.
Best viewed in 
| Above IE 9.0 version